Sustainable Bio-Tech
The tick Rhipicephalus microplus causes US$ 3.2 billion in annual losses in Brazilian livestock — and its range is expanding with climate change. Biotick develops vaccines to change this.
US$ 3.2B
in annual losses (Embrapa, 2024)
12%
of Brazil's herd is taurine
238M
head in Brazil's cattle herd
Who we are
Founded
2010
Biotick was founded in 2010 by a group of experienced entrepreneurs with a shared interest in tropical livestock farming. We combine decades of parasitology research with modern computational biology and AI tools to develop increasingly effective and scalable vaccine platforms.
Research & publications
Our collaborations with Embrapa and Butantan have produced scientific publications and a patented formulation based on selected synthetic peptides.
Scientific partners
Embrapa Gado de Corte
Instituto Butantan
Our approach stems from a deep understanding of the underlying science, leveraged by partnerships with Brazil's leading research institutions.
Computational biology & AI
AI-assisted R&D
Computational biology tools accelerate antigen design and vaccine platform development.
Next-gen platforms
Advancing beyond first-generation formulations using recombinant biotechnology and synthetic gene design.
Patented formulation
6
selected synthetic peptides in the vaccine formulation
The problem
Brazil has the world's largest commercial cattle herd — 238 million head — yet only 12% are high-productivity taurine breeds. The reason: the bovine tick.
The productivity gap
Zebu breeds (Bos indicus) dominate Brazil's herd due to their resistance to tick-borne diseases. But they fetch prices 30% lower on international markets and produce 3 to 5 times less milk than European breeds. Only 12% of Brazil's herd is taurine — versus 83% in Argentina and 81% in Australia.
US$ 3.2B
in annual losses caused by ticks in Brazilian livestock
Barros et al., Embrapa Gado de Corte, 2024The pesticide problem
Bovine ticks are currently controlled primarily through chemical acaricides — at a cost of R$ 75–100 per head/year — that are environmentally harmful and increasingly ineffective due to growing parasite resistance. Climate change is expanding the tick's range into previously free regions such as northern Argentina.
Resolving this problem through biotechnology — especially vaccines — will enable a shift to European breeds, bringing substantial productivity and sustainability gains. And this will be true not only for Brazil, but for tropical livestock farming across the planet.
How we operate
Biotick invests in the joint development of veterinary solutions with reputable research institutions, licensing or partnering with the best pharmaceutical companies in the sector to accelerate the introduction of these solutions into the global market.
Scientific partners
Get in touch
Investors, researchers, and industry partners are welcome.
Biotick Pesquisa e Desenvolvimento Tecnológico S.A.
Avenida Santo Amaro, 1047 – Suite 1008 – Vila Nova Conceição, 04505-001 – São Paulo – SP – Brazil
Social
LinkedIn
